Dimerix Ltd has released a press release.
Positive interim analysis of DMX-200 phase II data
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Appendix 4E
- Response to ASX Price and Volume Query
- Outcomes of DMX-200 pre-IND meeting with the FDA
- Update for NASH Pre-Clinical Program
- 10 Patient Milestone Reached. On Track to Report Trial Data.
Later from Dimerix
- Update presentation - interim data
- Appointment of Chief Executive Officer
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
- Dimerix Raises $2 million to Advance Clinical Program
- Key Patent Allowed in Japan
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix